论文部分内容阅读
目的:评价超早期应用尿激酶溶栓治疗急性脑梗死的疗效及安全性。方法:采用尿激酶(100万u～150万u/人次)超早期治疗急性脑梗死溶栓组30例,并设立同期对照组29例。在治疗前后对临床疗效(神经功能缺损评分、日常生活能力状态评分)、并发症、CT等方面进行比较分析。结果:与对照组比较,溶栓组在不同时间的治疗显效率都明显增高(P<0.05)。治疗组并发脑出血2例,1例因左额顶叶出血并发脑疝死亡(死亡率为6.64%);对照组并发梗死后出血1例,因大面积脑梗死并发脑疝死亡2例(死亡率为6.9%)。结论:超早期(6小时以内)静脉溶栓治疗急性脑梗死疗效明显,是一种有效、安全的治疗方法。
Objective: To evaluate the efficacy and safety of ultra-early application of urokinase thrombolysis in the treatment of acute cerebral infarction. Methods: Urokinase (1 million u ~ 1.5 million u / person times) ultra-early treatment of thrombolytic group of 30 cases of acute cerebral infarction, and the establishment of the same period in the control group of 29 cases. Before and after treatment of clinical efficacy (neurological deficit score, daily living ability score), complications, CT and other aspects of comparative analysis. Results: Compared with the control group, the effective rate of thrombolysis group was significantly increased at different times (P <0.05). Two cases of intracerebral hemorrhage occurred in the treatment group, one case died of herniation due to left frontal parietal lobe hemorrhage (6.64%). One case was complicated by cerebral infarction and two cases died of cerebral hernia due to large area cerebral infarction Rate of 6.9%). Conclusion: Ultra-early (within 6 hours) intravenous thrombolytic therapy of acute cerebral infarction obvious effect is an effective and safe treatment.